Zevra Therapeutics, Inc. (ZVRA)
$11.39+3.55%Close
SELLRECOVERY · day 3
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $673M
- Beta
- 0.98
- P/E (TTM)
- 11.17
- Short % float
- 13.01%
- Days to cover
- 7.2
- SI change
- +24.6%
- 1W
- +14.01%
- 1M
- -5.56%
- vs SPY 1W
- +12.85%
- vs SPY 1M
- -8.55%
Industry peers
FMP comparable companies · ranked by market cap
- NBIXSELLNeurocrine Biosciences, Inc.$14.6BRECOVERYQ 17$145.51+0.84%
- JAZZSELLJazz Pharmaceuticals plc$14.5BBEARQ 24$231.39-1.81%
- PRAXSELLPraxis Precision Medicines, Inc.$7.8BCRISISQ 11$280.14-1.40%
- ALKSSELLAlkermes plc$7.0BRECOVERYQ 6$41.65+1.25%
- XENESELLXenon Pharmaceuticals Inc.$3.5BCRISISQ 22$36.57+0.77%
- SUPNBUYSupernus Pharmaceuticals, Inc.$2.5BRECOVERYQ 26$42.83+1.26%
- GHRSSELLGH Research PLC$1.5BCRISISQ 16$21.52+3.23%
- ANROSELLAlto Neuroscience, Inc.$831MCRISISQ 17$23.69+1.41%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on ZVRA?
- LOPJLB’s latest quantitative signal on Zevra Therapeutics, Inc. (ZVRA) is SELL in a RECOVERY regime. Signals are updated daily.
- What market regime is ZVRA in?
- Zevra Therapeutics, Inc. (ZVRA) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does Zevra Therapeutics, Inc. (ZVRA) do?
- Zevra Therapeutics, Inc., founded in 2006 and based in Celebration, Florida, is a biopharmaceutical company dedicated to discovering and developing innovative treatments for rare diseases. The company employs its proprietary Ligand Activated Therapy (LAT) technology to create novel prodrug versions of existing FDA-approved medications or to enable new applications for other compounds, primarily…